The Bydureon Half-Life Explained (and Why It Matters)

Bydureon at a glance:

• Drug class: GLP-1 receptor agonist
• Manufacturer: AstraZeneca
• FDA approved: 2012
• Route: subcutaneous injection (single-dose pen)
• Typical frequency: once weekly
• Half-life: approximately 2 weeks (extended-release formulation)
• Cash price (US): $700-$800/month without insurance
• Receptor target: GLP-1 receptor

If you're looking up Bydureon half-life, you probably have a specific question: when can I switch, how long until it clears, what happens if I miss a dose. We answer all three below.

Half-Life Defined

The half-life is the time it takes for the concentration of a drug in the bloodstream to fall by half. It governs how often a drug needs to be dosed to maintain therapeutic levels and how long the drug persists after the last dose.

For Bydureon, the half-life is approximately 2 weeks (extended-release formulation). That number explains the once weekly dosing schedule.

Time to Steady State

After starting (or changing) a dose, drug levels reach a new "steady state" after about 5 half-lives.

For Bydureon: with a 5-7 day half-life, steady state at a new dose is reached around 4-5 weeks. That's why dose increases are spaced ~4 weeks apart in the standard titration schedule.

How Long Bydureon Stays in Your System

A common question: "if I stop Bydureon, how long does it stay in my body?"

The standard rule of thumb is that a drug is essentially cleared after 5 half-lives. For Bydureon: that's approximately 10 weeks. Effects on appetite, glucose, or other targets persist for a similar period before fully resolving.

For incretin agents specifically, the appetite-related effects fade over weeks after stopping.

Practical Implications

A long half-life:

• Allows less frequent dosing (better adherence)
• Smooths out peaks and troughs (often better tolerability)
• Means dose changes take longer to fully express
• Creates a longer "runway" if a dose is missed

A short half-life:

• Requires more frequent dosing
• Produces sharper concentration peaks (and matching side effects)
• Allows faster dose adjustments
• Provides faster clearance if stopped

Bydureon, with its long half-life, falls on the long end of this spectrum.

Half-Life and Missed Doses

If a dose is missed:

• Take the missed dose as soon as you remember if you're well within the dosing interval
• Skip it if you're closer to the next dose
• Never double up

The longer the half-life, the more forgiving the missed-dose window. For Bydureon, the missed-dose window is relatively forgiving.

Half-Life Across the Drug Class

Within the broader class of glp-1 receptor agonist, half-lives vary significantly. Daily agents (liraglutide) have shorter half-lives; weekly agents (semaglutide, dulaglutide, tirzepatide) have half-lives in the multi-day range. See our comparison pages for direct comparisons.

Bottom Line

If you only remember one thing about Bydureon pharmacokinetics, make it the half-life. Almost every other practical question traces back to it.

Frequently Asked Questions

Related Reading

• Bydureon: The Complete 2026 Guide (Mechanism, Dosing, Cost)
• Bydureon Side Effects: The Complete List and How to Handle Them
• What Results Should You Expect from Bydureon? A Practical Guide
• Bydureon Price Decoded: Insurance, Coupons, and Cash-Pay Options
• What Is Ozempic? Everything You Should Know Before Starting
• Is Ozempic Safe? An Honest Look at the Side-Effect Profile

Sources

• Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023;389:2221.
• Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989.
• Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016;375:1834.

This page is informational only and is not medical advice.